1. ICD-10-CM Codes
›
2. M00-M99 Diseases of the musculoskeletal system and connective tissue
›
3. M30-M36 Systemic connective tissue disorders
›
4. M33- Dermatopolymyositis
›
5. 2021 ICD-10-CM Diagnosis Code M33.2

2021 ICD-10-CM Diagnosis Code M33.2

Polymyositis

2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code

• M33.2 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
• The 2021 edition of ICD-10-CM M33.2 became effective on October 1, 2020.
• This is the American ICD-10-CM version of M33.2 - other international versions of ICD-10 M33.2 may differ.

• An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.
• An inflammatory disease of the muscles closest to the center of the body. It causes weakness, inability to stand, climb stairs, lift, or reach. It may also cause muscle pain and difficulty swallowing, and may affect the lungs and heart. Having polymyositis increases the risk of certain types of cancer.
• Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (drug toxicity); connective tissue diseases; infections; malignant neoplasms; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
• Inflammation of a number of voluntary muscles simultaneously.

• 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
• 2017 (effective 10/1/2016): No change
• 2018 (effective 10/1/2017): No change
• 2019 (effective 10/1/2018): No change
• 2020 (effective 10/1/2019): No change
• 2021 (effective 10/1/2020): No change

• Code Also: I27.21
  ICD-10-CM Diagnosis Code I27.21

  Secondary pulmonary arterial hypertension

  2018 - New Code 2019 2020 2021 Billable/Specific Code

  Applicable To

  • (Associated) (drug-induced) (toxin-induced) pulmonary arterial hypertension NOS
  • (Associated) (drug-induced) (toxin-induced) (secondary) group 1 pulmonary hypertension

  Code Also

  • associated conditions if applicable, or adverse effects of drugs or toxins, such as:
  • adverse effect of appetite depressants (T50.5X5)
  • congenital heart disease (Q20-Q28)
  • human immunodeficiency virus [HIV] disease (B20)
  • polymyositis (M33.2-)
  • portal hypertension (K76.6)
  • rheumatoid arthritis (M05.-)
  • schistosomiasis (B65.-)
  • Sjögren syndrome (M35.0-)
  • systemic sclerosis (M34.-)
• Type 1 Excludes: G72
  ICD-10-CM Diagnosis Code G72

  Other and unspecified myopathies

  2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code

  Type 1 Excludes

  • arthrogryposis multiplex congenita (Q74.3)
  • dermatopolymyositis (M33.-)
  • ischemic infarction of muscle (M62.2-)
  • myositis (M60.-)
  • polymyositis (M33.2.-)

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.